Stryker announces to acquire Inari

Stryker is making big moves—announcing its plan to acquire Inari Medical for a whopping $4.9 billion!

That’s $80 per share in cash for all outstanding stock of the innovative VTE-focused company.

Here’s why it’s huge:

Inari Medical, founded in 2011, is a leader in treating venous thromboembolism (VTE)—a condition that impacts up to 900,000 lives annually in the U.S.

Their tools focus on clot removal without thrombolytic drugs, which perfectly complements Stryker’s Neurovascular portfolio. 

Stryker CEO Kevin Lobo said:

"The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases."

Meanwhile, Inari CEO Drew Hykes is pumped:

"With Stryker’s capabilities and global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint."

This move is all about elevating care standards for conditions like deep vein thrombosis and pulmonary embolism, areas where Inari has already impacted hundreds of thousands of lives.

The deal’s expected to close by Q1 2025, pending approvals. More details will drop during Stryker’s earnings call on Jan 28, 2025.